- Home
- RGT vs STRO Comparison
RGT vs STRO Comparison
Compare RGT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGT | STRO |
|---|---|---|
| Founded | 1986 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.3M | 94.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RGT | STRO |
|---|---|---|
| Price | $12.78 | $9.95 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 22.4K | ★ 110.9K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | ★ $105,646,000.00 |
| Revenue This Year | N/A | $62.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.84 | $5.23 |
| 52 Week High | $11.08 | $24.80 |
Technical Indicators
Market Signals| Indicator | RGT | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 88.67 |
| Support Level | $12.68 | $7.88 |
| Resistance Level | $12.91 | $10.10 |
| Average True Range (ATR) | 0.14 | 0.67 |
| MACD | 0.04 | 0.64 |
| Stochastic Oscillator | 81.82 | 98.99 |
Price Performance
Historical ComparisonAbout RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.